ArticleJournal of experimental & clinical cancer research : CR2014

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.

Zhaomei Mu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.